Wellgistics Health Reports 85.6% Revenue Decline, Net Loss Improves in Latest Quarter

Wellgistics Health, Inc. reported significant financial challenges in its latest quarterly filing for the period ending March 31, 2026. The company generated net revenues of $1.56 million, a stark decline of approximately 85.6% compared to $10.86 million in the same period last year. This drop was primarily attributed to a substantial decrease in distribution revenues, which were impacted by liquidity constraints that hindered the company's ability to procure and fulfill product orders. In contrast, pharmacy retail revenues saw growth, increasing to $1.13 million from $114,676 year-over-year, reflecting the ongoing expansion of Wellgistics' pharmacy operations.

The company's gross profit for the quarter was $170,221, down from $692,641 in the prior year, resulting in a gross margin of 10.9%, an improvement from 6.4% in the previous year. This improvement was largely due to the higher margins associated with pharmacy retail revenues, despite the overall revenue decline. Total operating expenses decreased significantly to $6.19 million from $32.04 million, primarily due to a reduction in non-cash stock-based compensation expenses, which had inflated the previous year's figures.

Wellgistics Health's net loss for the quarter was $7.74 million, a notable improvement from a loss of $32.43 million in the same quarter of 2025. This reduction in loss was primarily driven by the absence of substantial stock-based compensation charges that had previously burdened the financials. However, the company continues to face challenges, including a working capital deficit of $29.44 million and an accumulated deficit of $118.77 million as of March 31, 2026, raising concerns about its ability to continue as a going concern.

In terms of operational developments, Wellgistics Health has been actively pursuing strategic initiatives to enhance its liquidity and operational capacity. The company raised $6.5 million through the issuance of secured convertible promissory notes in January 2026 and has plans for further financing. Additionally, a reverse stock split was approved to help regain compliance with Nasdaq's minimum bid price requirement. The company is also focusing on expanding its pharmacy operations and distribution network while reducing operating expenses.

Looking ahead, Wellgistics Health aims to leverage its technology platform and pharmacy operations to improve patient outcomes and increase market share. The company is exploring partnerships and collaborations to enhance its service offerings and is committed to addressing its liquidity challenges through various financing strategies. However, management has acknowledged that there can be no assurance of success in these endeavors, and the company remains under scrutiny regarding its compliance with Nasdaq listing requirements.